PCSK9抑制剂的专利纷争:美国陪审团支持安进的PCSK9抑制剂Repatha

2019-02-27 不详 网络

安进公司近日宣布,美国特拉华州陪审团作出判决,维护两项与PCSK9抑制剂Repatha(evolocumab)相关专利的有效性。该决定是在2016年的一项审判之后做出的,美国联邦陪审团认定保护Repatha的两项专利,这些专利已被Sanofi和Regeneron的PCSK9抑制剂Praluent(alirocumab)侵犯。

安进公司近日宣布,美国特拉华州陪审团作出判决,维护两项与PCSK9抑制剂Repathaevolocumab)相关专利的有效性。该决定是在2016年的一项审判之后做出的,美国联邦陪审团认定保护Repatha的两项专利,这些专利已被SanofiRegeneronPCSK9抑制剂Praluentalirocumab)侵犯。

根据安进的说法,这些专利描述并声称抗体evolocumabPCSK9上的特定区域结合并降低体内LDL-胆固醇水平。安进公司首席执行官罗伯特·布拉德韦表示,最新的裁决是在最近欧洲专利局和日本专利局的决定之后做出的,该裁决还拒绝了SanofiRegeneron以及其他公司提出的PCSK9抗体专利有效性的质疑。但SanofiRegeneron表示要在未来几个月推翻判决并要求重新审判。与此同时,他们指出,该裁决并未影响美国医生和患者获得Praluent的权利


原始出处:

http://www.firstwordpharma.com/node/1626799#axzz5gcsvw92A

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-07-10 Tamikia
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-12-31 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-09-29 FukaiBao
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-03-01 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-03-01 zhouqu_8
  7. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-03-01 mei538
  8. [GetPortalCommentsPageByObjectIdResponse(id=1685621, encodeId=e383168562131, content=<a href='/topic/show?id=a340138e48a' target=_blank style='color:#2F92EE;'>#PCS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13874, encryptionId=a340138e48a, topicName=PCS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173d28230918, createdName=Tamikia, createdTime=Wed Jul 10 21:23:00 CST 2019, time=2019-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851928, encodeId=7d2d1851928f8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Dec 31 02:23:00 CST 2019, time=2019-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777277, encodeId=0cc71e7727762, content=<a href='/topic/show?id=678d5348a6' target=_blank style='color:#2F92EE;'>#Csk#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5348, encryptionId=678d5348a6, topicName=Csk)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979839152460, createdName=FukaiBao, createdTime=Sun Sep 29 19:23:00 CST 2019, time=2019-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786866, encodeId=09671e8686663, content=<a href='/topic/show?id=4c5b138824d' target=_blank style='color:#2F92EE;'>#PCSK9抑制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13882, encryptionId=4c5b138824d, topicName=PCSK9抑制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Tue Aug 13 09:23:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427302, encodeId=c32e142e30226, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541437, encodeId=655f154143ee5, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621267, encodeId=a92a162126eb4, content=<a href='/topic/show?id=bdf61532e21' target=_blank style='color:#2F92EE;'>#Repatha#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15327, encryptionId=bdf61532e21, topicName=Repatha)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d4f620230812, createdName=mei538, createdTime=Fri Mar 01 09:23:00 CST 2019, time=2019-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361644, encodeId=257936164418, content=抑制剂的临床应用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Thu Feb 28 06:54:43 CST 2019, time=2019-02-28, status=1, ipAttribution=)]
    2019-02-28 jyzxjiangqin

    抑制剂的临床应用。

    0

相关资讯

JAHA:HIV患者血清PCSK9水平与冠脉内皮功能呈负相关

HIV阳性病人患冠心病的风险会增高,但具体机制尚未阐明。本研究纳入分析了48例接受抗病毒治疗的无冠心病的HIV阳性患者,以及15例年龄和低密度脂蛋白胆固醇匹配的正常对照,对其进行磁共振检查以评估冠脉内皮功能,并抽取血样检测血清PCSK9水平和血管标志物水平。分析结果显示,HIV阳性患者的血清PCSK9水平高出正常对照65%(P<0.0001),且HIV患者的冠脉内皮功能明显降低,并与血清PC

Diabetes Obes Metab:血浆PCSK9与2型糖尿病患者心血管事件!

由此可见,PCSK9与T2DM人群CV事件之间的相关性并不一致。这种关联可能取决于CV风险水平和基础治疗。

Metabolism:杂合子家族性高胆固醇血症Lp(a)与PCSK9之间的相关性分析!

由此可见,HeFH患者血浆Lp(a)水平与PCSK9相关,提示对FH患者中PCSK9与LP(a)之间的相互作用需要进一步探索。

Circulation:他汀和PCSK9联合治疗的患者的残余炎症风险

他汀类药物联合PCSK9(9型前体蛋白转化酶枯草杆菌蛋白酶/kexin)抑制可显著降低低密度脂蛋白(LDL-C)和心血管事件率。目前尚不明确,在治疗后,以高灵敏度的C反应蛋白(hsCRP)所衡量的残余炎症风险是否仍是此类患者的重要临床问题。研究人员在参与SPIRE-1和SPIRE-2心血管预后试验的采用他汀和bococizumab联合治疗的9738位患者中,根据治疗14周时检测的hsCRP和LDL

李建军:药物机制是PCSK9抑制剂临床获益的有力保证

追本溯源:动脉粥样硬化本质是脂质参与的炎症反应 ESC 2018上,动脉粥样硬化(AS)的发病机制和干预策略再次成为学者们关注的焦点。一方面,LDL-C在AS进程中的核心作用得到了不断积累的证据支持。机制研究显示,LDL-C对AS的作用贯穿AS斑块形成、进展和结局的始终,主要表现为增加斑块的不稳定性,最终导致斑块破裂和血栓形成。ESC 2018上报告的一项纳入超过200万受试者、2000

JACC:PCSK9可作为心衰患者预后的预测因子

前蛋白转化酶枯草溶菌素9(PCSK9)可以靶向结合低密度脂蛋白受体(LDLR),防止其再循环利用。因此,PCSK9可作为动脉粥样硬化的预测因子和药物的靶点。本研究的目的是评估PCSK9-LDLR对心衰患者是否有降低动脉粥样硬化风险的作用。本研究纳入的是BIOSTAT-CHF临床试验中的心衰患者,主要终点事件是全因死亡率、心衰的复合死亡率和心衰的住院率。最终共纳入了2174名心衰患者(平均年龄为68